Abstract

BackgroundThe present study aimed to assess the correlation of fibroblast growth factor (FGF)-23 expression with clinical characteristics, then further explore its value in predicting 2-year in-stent restenosis (ISR) risk in coronary heart disease (CHD) patients underwent percutaneous coronary intervention (PCI) with drug-eluting stent (DES).MethodsIn this prospective, single-center, observational study, totally 214 CHD patients treated by PCI with DES were consecutively recruited, and peripheral blood samples were collected prior to PCI with DES for serum samples isolation. Following, FGF-23 level in the serum samples was detected via enzyme linked-immuno-sorbent Assay. The follow-up coronary angiography was performed at 1 year and 2 years after PCI or if suspected ISR symptoms occurred.ResultsFGF-23 was positively correlated with fasting blood-glucose, insulin resistance, serum creatinine, serum uric acid, LDL-C, high-sensitivity C-reactive protein, cardiac troponin I and N-terminal-proB-type natriuretic peptide, while was negatively associated with HDL-C and left ventricular ejection fraction (all P < 0.01). Furthermore, FGF-23 was positively correlated with hypercholesteremia, hyperuricemia and family history of CAD (all P < 0.05). However, it did not correlate with other chronic complications, biochemical indexes, lesion features or PCI parameters (all P > 0.05). Moreover, FGF-23 level was higher in 2-year ISR patients (n = 38) compared to 2-year non-ISR patients (n = 176) (P < 0.001), and receiver operating characteristic curve indicated that FGF-23 was of good value in predicting 2-year ISR risk (AUC 0.828, 95% CI 0.761–0.896).ConclusionFGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree of target lesion, and serves as an independent risk factor for 2-year ISR risk in CHD patients underwent PCI with DES.

Highlights

  • The present study aimed to assess the correlation of fibroblast growth factor (FGF)-23 expression with clinical characteristics, further explore its value in predicting 2-year in-stent restenosis (ISR) risk in coronary heart disease (CHD) patients underwent percutaneous coronary intervention (PCI) with drug-eluting stent (DES)

  • FGF-23 is reported to be implicated in the regulation of phosphatemia and mineral metabolism via interacting with its co-receptor klotho in kidney, and growing recent clinical evidences demonstrate the regulatory role of FGF-23 in diverse pathological processes of cardiovascular diseases and potential of FGF-23 as a clinical biomarker for predicting higher risk of adverse cardiovascular outcomes [8,9,10]

  • The aforementioned data suggests the contribution of FGF-23 on development of cardiovascular injury and coronary stenosis, we hypothesized that FGF-23 might be correlated with ISR risk in CHD patients treated by PCI with DES, study related to the predictive potential of FGF-23 in ISR risk has not been conducted yet

Read more

Summary

Introduction

The present study aimed to assess the correlation of fibroblast growth factor (FGF)-23 expression with clinical characteristics, further explore its value in predicting 2-year in-stent restenosis (ISR) risk in coronary heart disease (CHD) patients underwent percutaneous coronary intervention (PCI) with drug-eluting stent (DES). FGF-23 is associated with accelerated plaque calcification as well as advanced severity of atherosclerosis in terms of vascular plaque burden, and it functions as a risk factor for coronary artery stenosis as well as adverse cardiovascular outcomes in CHD patients [11]. The present study was conducted to detect the correlation of FGF-23 expression with clinical characteristics, and further to explore its value in predicting 2-year ISR risk in CHD patients underwent PCI with DES

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call